We anticipate the webcast will last about 75 minutes. The remaining time will be available for your questions. He will then conclude with our 2020 guidance, and qualitative expectations as we’re positioned for a strong start to 2021. Joe will provide high level commentary about our enterprise performance, including J&J's response to COVID-19 followed by insights into our capital allocation priorities as well as some key pipeline updates. My comments on the segments will be shared at a high-level to allow more time for Q&A. I will cover consolidated and segment sales information, along with some operational highlights from the P&L results for the corporation and the three business segments. This slide acknowledges those relationships. Several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. A further description of these risks, uncertainties and other factors can be found in our SEC filings, including our 2019 Form 10-K, and subsequent Form 10-Qs, along with a reconciliation of the non-GAAP financial measures utilized for today's discussion to the most comparable GAAP measures are also available at. This means the results could change at any time and the contemplated impact of COVID-19 on the company's business results and outlook is a best estimate based on the information available as of today's date. In particular, there is significant uncertainty about the duration and contemplated impact of the COVID-19 pandemic.
We encourage you to review the cautionary statement included in today's presentation, which identifies certain risks and factors that may cause the company's actual results to differ materially from those projected. Please note that today's presentation includes forward-looking statements. This review is being made available via webcast accessible through the Investor Relations section of the Johnson & Johnson website at, where you can also find additional materials, including today's presentation and associated schedules. During the Q&A portion of the call, we will be joined by Jennifer Taubert, Executive Vice President and Worldwide Chairman, Pharmaceuticals Ashley McEvoy, Executive Vice President and Worldwide Chairman, Medical Devices Thibaut Mongon, Executive Vice President and Worldwide Chairman, Consumer Health and Mathai Mammen, Global Head of Janssen Research & Development.Ī few logistics before we get into the details. Joining me on today’s call is Joe Wolk, Executive Vice President, Chief Financial Officer. I hope everyone is healthy and continues to remain safe during these times. Welcome to our company's review of business results for the third quarter of 2020. This is Chris DelOrefice, Vice President of Investor Relations for Johnson & Johnson. I would now like to turn the conference call over to Johnson & Johnson.
All participants will be in listen-only mode until the question-and-answer session of the conference. Good morning, and welcome to Johnson & Johnson's Third Quarter 2020 Earnings Conference Call. Mathai Mammen - Global Head of Janssen Research & Development Thibaut Mongon - Executive Vice President and Worldwide Chairman, Consumer Health Jennifer Taubert - Executive Vice President and Worldwide Chairman, PharmaceuticalsĪshley McEvoy - Executive Vice President and Worldwide Chairman, Medical Devices Joe Wolk - Executive Vice President, Chief Financial Officer Johnson & Johnson ( NYSE: JNJ) Q3 2020 Results Conference Call Octo8:30 AM ET
0 kommentar(er)
